A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning
This study is designed to determine whether Umbilical Cord Transplantation (UCB) can be substituted for adult bone marrow cells in the standard stem cell transplant regimens used at this hospital for subjects who do not have stem cell donors.
NCT00676806 — Multiple Myeloma
Status: Completed
http://inclinicaltrials.com/multiple-myeloma/NCT00676806/
Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR
The objective of this study is to determine whether there are alterations in the population of endothelial progenitor cells in umbilical cord blood samples of infants born in the setting of maternal preeclampsia or fetal growth restriction.
NCT00634855 — Preeclampsia
Status: Terminated
http://inclinicaltrials.com/preeclampsia/NCT00634855/
Total Body Irradiation With Fludarabine Conditioning Followed by Transplantation With Combined Umbilical Cord Blood Grafts
Results to date of umbilical cord blood transplantation in adult and fully mature adolescent patients are inferior to what is seen in children, due to a lower stem cell dosage in adults and a more toxic conditioning regimen. This phase 1 protocol will use a potentially less toxic bone marrow conditioning regimen, followed by infusion of a combined umbilical cord blood graft that will provide the patient with a higher stem cell dose than can be given with a single umbilical cord blood infusion. The subjects will be conditioned with a total body irradiation (TBI) 13.5 Gy and fludarabine. Following conditioning, up to two unrelated, partially matched umbilical cord blood grafts will be infused that will provide a minimum nucleated cell dose of 3 x 10e7/kg . The primary objective of this study is to measure the frequency of treatment-related toxicity and engraftment.
NCT00606437 — Lymphoma
Status: Completed
http://inclinicaltrials.com/lymphoma/NCT00606437/
Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation
The objective of this trial is to assess the toxicity of thymus transplantation following unrelated umbilical cord blood transplantation. Emphasis will be placed on adverse events that are not typically associated with umbilical cord blood transplantation. Also, to determine whether engraftment of a third party thymus allograft is feasible in patients who have undergone unrelated umbilical cord blood transplantation.
NCT00597441 — Stem Cell Transplantation
Status: Terminated
http://inclinicaltrials.com/stem-cell-transplantation/NCT00597441/
Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy Study 1. Phase I Study of Feasibility and Safety.
This is a pilot study to test feasibility of collection, preparation and infusion of a baby's own (autologous)umbilical cord blood in the first 14 days after birth if the baby is born with signs of brain injury.
NCT00593242 — Neonatal Hypoxic Ischemic Encephalopathy
Status: Completed
http://inclinicaltrials.com/neonatal-hypoxic-ischemic-encephalopathy/NCT00593242/
UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies
The researchers want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.
NCT00578045 — Multiple Myeloma
Status: Withdrawn
http://inclinicaltrials.com/multiple-myeloma/NCT00578045/
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This clinical trial is studying how well four different chemotherapy regimens given with or without total-body irradiation before umbilical cord blood transplant work in treating patients with relapsed or refractory hematologic cancer.
NCT00547196 — Lymphoma
Status: Completed
http://inclinicaltrials.com/lymphoma/NCT00547196/
Characteristics of Cord Blood Immunologic Parameters of Infants < 32 Weeks Gestation
Infants in the NICU are at high risk for morbidity and mortality from infections of any onset. Diagnosis of these infections is imperfect at best. Patterns of inflammatory and regulatory proteins (cytokines & chemokines, in addition to antigen detection on antibody secreting cells (ASC's)may provide a more accurate and rapid approach to diagnosis of infections in these high-risk patients.
NCT00524394 — Sepsis
Status: Terminated
http://inclinicaltrials.com/sepsis/NCT00524394/
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
This is a pilot study designed to evaluate the safety and feasibility of performing umbilical cord blood transplants in adults with high-risk hematopoietic malignancies. A novel myeloablative preparative regimen will be used. One, up to a maximum of three cord blood units will be administered to facilitate engraftment.
NCT00514722 — Multiple Myeloma
Status: Terminated
http://inclinicaltrials.com/multiple-myeloma/NCT00514722/
A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults With Hematologic Malignancy
The hypothesis of the study is double unit umbilical cord blood transplantation in adults will be associated with a one year survival rate of at least 40%.
NCT00514579 — Hematologic Malignancies
Status: Completed
http://inclinicaltrials.com/hematologic-malignancies/NCT00514579/